Accurate characterization of microbial communities in low-biomass environments—such as human tissues, treated drinking water, and air—is pivotal for advancements in biomedical research, diagnostics, and drug development.
Accurate microbial profiling of low-biomass specimens—such as respiratory, tissue, and skin samples—is critical for clinical diagnostics and drug development but is notoriously challenged by contamination, PCR bias, and stochastic effects.
Profiling microbial communities in low-biomass environments—such as human tissues, cleanrooms, and extreme ecosystems—presents unique challenges that can compromise data integrity and biological conclusions.
Metagenomic sequencing of low-biomass samples, such as urine, respiratory fluids, and tissues, is critically hampered by overwhelming host DNA, which can obscure microbial signals and lead to spurious results.
High-throughput sequencing has revolutionized microbiome and transcriptome research, but its reliance on relative abundance data hinders accurate cross-sample comparison and can lead to misinterpretation.
This article provides a comprehensive guide for researchers and drug development professionals on using Digital PCR (dPCR) for absolute abundance measurements.
Droplet Digital PCR (ddPCR) is revolutionizing microbiome research by enabling absolute, sensitive quantification of low-abundance nucleic acid targets in complex biological samples.
This article provides a comprehensive resource for researchers and drug development professionals tackling the analytical challenges of single-cell enumeration in low-biomass samples.
This article provides a systematic framework for researchers, scientists, and drug development professionals grappling with the challenge of false positives in low-biomass microbiome studies.
This article provides a comprehensive guide for researchers and drug development professionals grappling with the complexities of low-biomass microbiome studies.